Bijuva (Estradiol/Progesterone) Patent Expiration, LOE Window & CMS Spending

Bijuva (Estradiol/Progesterone) by Mayne: FDA Orange Book core substance LOE 2032-11-21, 0 AB generics, $1.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMayne
FDA Application & PathwayN210132 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-11-21
Last Listed Patent or Exclusivity Date2032-11-21
Orange Book Patents (*PED Extensions)24 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$728K
2024 Medicaid Spend$648K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel